Old Web
English
Sign In
Acemap
>
authorDetail
>
Lynn Wildonger
Lynn Wildonger
Merck & Co.
Pharmacology
Platelet
Medicine
Aspirin
Anesthesia
3
Papers
86
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
THE COX-2 INHIBITOR ETORICOXIB DID NOT ALTER THE ANTI-PLATELET EFFECTS OF LOW-DOSE ASPIRIN IN HEALTHY VOLUNTEERS.
2001
Arthritis & Rheumatism
John A. Wagner
Walter K. Kraft
Joanne Burke
Peggy H. Wong
Melanie Gleave
Lynn Wildonger
David L. Ebel
Sandi Vanburen
Keith M. Gottesdiener
Scott A. Waldman
Howard E. Greenberg
Show All
Source
Cite
Save
Citations (7)
A New Cyclooxygenase‐2 Inhibitor, Rofecoxib (VIOXX®), Did Not Alter the Antiplatelet Effects of Low‐Dose Aspirin in Healthy Volunteers
2000
The Journal of Clinical Pharmacology
Howard E. Greenberg
Keith M. Gottesdiener
Martha Huntington
Peggy Wong
Pat Larson
Lynn Wildonger
Lisa Gillen
Ellen P. Dorval
Scott A. Waldman
Show All
Source
Cite
Save
Citations (70)
MK-0966, a cyclooxygenase-2 (COX-2) specific inhibitor, had no effect on the anti-platelet activity of low-dose aspirin (ASA) measured by serum thromboxane B2 (TXB2) production and platelet aggregation.
1999
Clinical Pharmacology & Therapeutics
H.E. Greenberg
L.P. Gillen
E.P. Dorval
Lynn Wildonger
Patrick Larson
Martha Huntington
Peggy Wong
Keith M. Gottesdiener
S.A. Waldman
Show All
Source
Cite
Save
Citations (9)
1